The ALK gene rearrangement is the second most common driver genomic alteration accounting for approximately 3% to 7% of patients with approved targeted therapies in NSCLC, after EGFR gene mutations. We here describe a rare case of a patient with STRN-ALK–rearranged NSCLC. READ ARTICLE
Journal of thoracic Oncology DOI: 10.1016/j.jtocrr.2020.100125
Authors: Misako Nagasaka, Nagaratna Sarvadevabatla, Shawn Iwata, Yubin Ge, Ammar Sukari, Christian Klosowski, Ronald Yanagihara